Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rosindol: A fluorogen for the quantitative measurement of reactive oxygen species in living cells.

bioRxiv : the preprint server for biology·2026
Same author

Coil-Tag Conjugation: A Next Gen Site-Specific ADC Fabrication Technology.

Bioconjugate insights·2026
Same author

Peptide Tag-nology for Preparation of Site-Specific Antibody-Drug Conjugates.

Bioconjugate chemistry·2026
Same author

Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearance.

bioRxiv : the preprint server for biology·2026
Same author

A 3D microfluidic model of exchange between perfused blood and lymphatic microvascular networks.

Lab on a chip·2026
Same author

Supramolecular coiled-coil peptide platform for site-specific antibody drug conjugate engineering.

Nature communications·2026

Related Experiment Video

Updated: Feb 28, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

Self-amplifying RNA-based CAR T cell therapy with enhanced duration and multi-genic logic functions.

Yuyang Gu1, Jaehoon Choi2,3, Devin Mutha4

  • 1Division of Materials Science & Engineering, Boston University, Boston, MA, USA.

Biorxiv : the Preprint Server for Biology
|February 27, 2026
PubMed
Summary

Self-amplifying RNA (saRNA) CAR T cells offer a safer, more effective alternative to traditional viral vector methods for treating blood cancers. This novel saRNA platform enhances CAR T cell durability and tumor control, improving patient outcomes.

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.0K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.5K

Related Experiment Videos

Last Updated: Feb 28, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.0K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.5K

Area of Science:

  • Immunotherapy
  • Molecular Biology
  • Oncology

Background:

  • Chimeric antigen receptor T (CAR-T) cell therapy is a promising treatment for hematological malignancies.
  • Current CAR-T manufacturing using viral vectors is expensive, time-consuming, and carries risks like insertional mutagenesis.
  • Messenger RNA (mRNA) CAR T cells offer improved safety and speed but require frequent dosing due to short expression.

Purpose of the Study:

  • To develop and evaluate a modified self-amplifying RNA (saRNA) platform for CAR T cell engineering.
  • To assess the efficacy and durability of saRNA CAR T cells compared to mRNA CAR T cells.
  • To explore the potential of saRNA for advanced CAR T cell designs.

Main Methods:

  • Engineering CAR T cells using a modified self-amplifying RNA (saRNA) platform.
  • Evaluating saRNA CAR T cell performance in an acute lymphoblastic leukemia (ALL) xenograft model.
  • Assessing the co-expression capabilities of saRNA for advanced CAR systems.

Main Results:

  • saRNA CAR T cells demonstrated prolonged CAR expression and enhanced durability of tumor control compared to mRNA CAR T cells.
  • Superior tumor suppression and prolonged survival were observed in the ALL xenograft model using saRNA CAR T cells.
  • The saRNA platform successfully enabled co-expression of multiple proteins for advanced CAR designs like logic-gated CAR T cells.

Conclusions:

  • The modified saRNA platform offers a powerful and versatile approach for CAR T cell engineering.
  • saRNA CAR T cells present a favorable safety, efficacy, and accessibility profile for cancer therapy.
  • This technology has the potential to advance CAR T cell therapy for hematological malignancies and beyond.